Literature DB >> 22860166

ACS chemical neuroscience molecule spotlight on STX209 (arbaclofen).

Corey R Hopkins1.   

Abstract

STX209 (arbaclofen) is a γ-amino butyric acid type B (GABA(B)) receptor agonist from Seaside Therapeutics currently in clinical trials for autism spectrum disorders (ASD). The company has initiated a phase 2b study after positive results from a phase 2a trial, announced September 2010 (http://www.seasidetherapeutics.com/sites/default/files/STX209_ASD_P2b Trial_Initiation%206%2021%202011%20Final.pdf).

Entities:  

Keywords:  GABA; STX209; autism spectrum disorder (ASD)

Mesh：

Substances：

Year:  2011        PMID： 22860166      PMCID： PMC3369760          DOI： 10.1021/cn200061g

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN： 1948-7193            Impact factor:   4.418


  2 in total

1.  Recent advances in the design and development of novel negative allosteric modulators of mGlu(5).

Authors:  Kyle A Emmitte
Journal:  ACS Chem Neurosci       Date:  2011-08-17       Impact factor: 4.418

Review 2.  Fragile X syndrome: an update on developing treatment modalities.

Authors:  Aileen Healy; Roger Rush; Timothy Ocain
Journal:  ACS Chem Neurosci       Date:  2011-03-22       Impact factor: 4.418
  2 in total
  2 in total

1.  Spontaneous resting-state gamma oscillations are not predictive of autistic traits in the general population.

Authors:  Kristel De Groot; Jan W Van Strien
Journal:  Eur J Neurosci       Date:  2018-06-19       Impact factor: 3.386

2.  From bench to bedside: The mGluR5 system in people with and without Autism Spectrum Disorder and animal model systems.

Authors:  Cornelia Carey; Nisha Singh; Joel T Dunn; Teresa Sementa; Maria Andreina Mendez; Hester Velthuis; Andreia C Pereira; Charlotte Marie Pretzsch; Jamie Horder; Stefan Hader; David J Lythgoe; Diana-Georgina Rotaru; Anthony Gee; Diana Cash; Mattia Veronese; Declan Murphy; Grainne McAlonan
Journal:  Transl Psychiatry       Date:  2022-09-20       Impact factor: 7.989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.